Literature DB >> 27546483

Performance of the Peto odds ratio compared to the usual odds ratio estimator in the case of rare events.

A Catharina Brockhaus1,2, Ulrich Grouven3, Ralf Bender3,4.   

Abstract

For the calculation of relative measures such as risk ratio (RR) and odds ratio (OR) in a single study, additional approaches are required for the case of zero events. In the case of zero events in one treatment arm, the Peto odds ratio (POR) can be calculated without continuity correction, and is currently the relative effect estimation method of choice for binary data with rare events. The aim of this simulation study is a variegated comparison of the estimated OR and estimated POR with the true OR in a single study with two parallel groups without confounders in data situations where the POR is currently recommended. This comparison was performed by means of several performance measures, that is the coverage, confidence interval (CI) width, mean squared error (MSE), and mean percentage error (MPE). We demonstrated that the estimator for the POR does not outperform the estimator for the OR for all the performance measures investigated. In the case of rare events, small treatment effects and similar group sizes, we demonstrated that the estimator for the POR performed better than the estimator for the OR only regarding the coverage and MPE, but not the CI width and MSE. For larger effects and unbalanced group size ratios, the coverage and MPE of the estimator for the POR were inappropriate. As in practice the true effect is unknown, the POR method should be applied only with the utmost caution.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Keywords:  Effect measure; Performance measure; Peto odds ratio; Rare events; Simulation

Mesh:

Year:  2016        PMID: 27546483     DOI: 10.1002/bimj.201600034

Source DB:  PubMed          Journal:  Biom J        ISSN: 0323-3847            Impact factor:   2.207


  7 in total

1.  Trajectories of depressive symptoms among mothers of preterm and full-term infants in a national sample.

Authors:  Danielle Roubinov; Rashelle J Musci; Alison E Hipwell; Guojing Wu; Hudson Santos; Jennifer N Felder; Sabrina Faleschini; Elisabeth Conradt; Cindy T McEvoy; Barry M Lester; Claudia Buss; Amy J Elliott; José F Cordero; Annemarie Stroustrup; Nicole R Bush
Journal:  Arch Womens Ment Health       Date:  2022-06-16       Impact factor: 4.405

2.  Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials.

Authors:  Roni Nitecki; Alexander Melamed; Allison A Gockley; Jessica Floyd; Kate J Krause; Robert L Coleman; Ursula A Matulonis; Sharon H Giordano; Karen H Lu; J Alejandro Rauh-Hain
Journal:  Gynecol Oncol       Date:  2021-03-15       Impact factor: 5.304

Review 3.  Antiphospholipid Antibodies and Autoimmune Haemolytic Anaemia: A Systematic Review and Meta-Analysis.

Authors:  Paul R J Ames; Mira Merashli; Tommaso Bucci; Daniele Pastori; Pasquale Pignatelli; Alessia Arcaro; Fabrizio Gentile
Journal:  Int J Mol Sci       Date:  2020-06-09       Impact factor: 5.923

4.  Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis.

Authors:  Caroline McHutchison; Gordon W Blair; Jason P Appleton; Francesca M Chappell; Fergus Doubal; Philip M Bath; Joanna M Wardlaw
Journal:  Stroke       Date:  2020-07-10       Impact factor: 7.914

5.  The Clinical Implications and Complications of Anterior Versus Posterior Surgery for Multilevel Cervical Ossification of the Posterior Longitudinal Ligament; An Updated Systematic Review and Meta-Analysis.

Authors:  Dong Hwan Kim; Chang-Hyun Lee; Young San Ko; Seung Heon Yang; Chi Heon Kim; Sung Bae Park; Chun Kee Chung
Journal:  Neurospine       Date:  2019-09-30

6.  Antiphospholipid Antibodies in Sickle Cell Disease: A Systematic Review and Exploratory Meta-Analysis.

Authors:  Mira Merashli; Alessia Arcaro; Maria Graf; Matilde Caruso; Paul R J Ames; Fabrizio Gentile
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

7.  Safety and Efficacy of Adult Stem Cell Therapy for Acute Myocardial Infarction and Ischemic Heart Failure (SafeCell Heart): A Systematic Review and Meta-Analysis.

Authors:  Manoj M Lalu; Sasha Mazzarello; Jennifer Zlepnig; Yuan Yi Ryan Dong; Joshua Montroy; Lauralyn McIntyre; P J Devereaux; Duncan J Stewart; C David Mazer; Carly C Barron; Daniel I McIsaac; Dean A Fergusson
Journal:  Stem Cells Transl Med       Date:  2018-09-26       Impact factor: 6.940

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.